麻豆传媒

The once-weekly bettered placebo in reducing risk for heart events in patients with type 2 diabetes, the maker Eli Lilly announced. The REWIND trial met the primary endpoint for a reduction in a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke, although Lilly didn't provide the magnitude of benefit.

The FDA approved a new bio-identical hormone therapy combination treatment for moderate to severe vasomotor symptoms of menopause, TherapeuticsMD announced.

Although diabetes -- both type 1 and type 2 -- was tied to an increased risk for heart attack in both men and women in a new study, this associated . "These findings highlight the importance of raising awareness around the risk of heart attack women face, and ensuring that women as well as men have access to guideline-based treatments for diabetes and high blood pressure, and to resources to help them stop smoking," said lead author Elizabeth Millett, PhD, of The George Institute for Global Health at the University of Oxford, England, in a statement. (The BMJ)

However in another study, type 2 diabetes was tied to increased risk for , but not women. (British Journal of Cancer)

Antibiotics and antacids given to babies and children younger than age 2 might be tied to an increased risk for . (Gut)

Some type 1 diabetes patients in Britain may be missing out on beneficial since they are recommended only in certain regions, according to an investigation published in The BMJ. Currently, Abbott's FreeStyle Libre is the only system available in the U.K.

The FDA released final guidance detailing dates and rules for complying with , with a final compliance date of 2020 for manufacturers with more than $10 million in food sales. (The National Law Review)

A study assessing the performance of the -- used to distinguish between malignant and benign thyroid nodules -- showed 94% accuracy in identifying cancerous nodules. "Since thyroid cancer is known to progress differently based on the mutation involved, ThyroSeq potentially allows physicians to employ a precision medicine approach, modifying treatment for each patient based on the mutations present," said lead author David Steward, MD, of the University of Cincinnati, in a statement. (JAMA Oncology)

Comment